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Fanconi syndrome (FS) is a rare condition that is characterized by defects in the
proximal tubular function. A 48-year-old woman was admitted for evaluation of
proteinuria. The patient showed normal anion gap acidosis, normoglycemic glycosuria,
hypophosphatemia, and hypouricemia. Thus, her condition was compatible with FS.
The M peak was found behind the beta globulin region in urine protein electrophoresis.
Upon bone marrow examination, we found that 24% of cells were CD138þ plasma cells
with kappa restriction. From a kidney biopsy, we found crystalline inclusions within
proximal tubular epithelial cells. Thereafter, she was diagnosed with FS accompanied
by multiple myeloma. The patient received chemotherapy and autologous stem cell
transplantation, and obtained very good partial hematologic response. However,
proximal tubular dysfunction was persistent until 1 year after autologous stem cell
transplantation. In short, we report a case of FS accompanied by multiple myeloma,
demonstrating crystalline inclusion in proximal tubular cells on kidney biopsy.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fanconi syndrome (FS) is a rare disease characterized by
defects in proximal tubular function, including impairment of
reabsorption of solutes such as glucose, uric acid, phosphate,
amino acid, and bicarbonate [1]. Patients with FS may present
normoglycemic glycosuria, low molecular weight proteinuria,
hypophosphatemia, and normal anion gap metabolic acidosis.
It has been described that Multiple myeloma may induce
tubular dysfunction and FS [2]. Multiple myeloma is a neoplasticn Society of Nephrology. Publi
c-nd/4.0/).
y, Department of Internal
wan University School of
5–710, Korea.
JE Lee).bone marrow disease characterized by clonal proliferation of
plasma cells and overproduction of monoclonal protein [3]. Free
light chain overproduction is associated with toxic effects to
proximal tubular cells in the kidneys, which may induce FS [4].
In this case, the patient who had presented proteinuria
initially was diagnosed with FS and multiple myeloma, after
reviewing her results from blood laboratory work, urine analysis,
and bone marrow examination. In addition, kidney pathology
conﬁrmed the presence of rod-shaped casts in proximal tubules.Case report
A 48-year-old woman visited the nephrology clinic for
proteinuria, which was detected at a local hospital. She had
been producing foamy urine and experiencing nocturia forshed by Elsevier. This is an open access article under the CC BY-NC-ND
Table 1. Renal and hematologic laboratory results at baseline and
during treatmentn
Admission
(October
2012)
Prior to
transplantation
(February 2013)
After 1 year
from
transplantation
(March 2014)†
Serum phosphate
(mg/dL)
2.3 1.5 3.0
Serum uric acid
(mg/dL)
0.9 0.8 1.3
Serum HCO3
(mmol/L)
15.9 15.3 22.5 (tCO2)
Serum potassium
(mmol/L)
3.1 3.3 4.0
Glycosuria þþ þþþþ þþ
(S.G. 1.036) (S.G. 1.020) (S.G. 1.015)
Albumin/
creatinine ratio
(μg/mgCr)
401.69 – 439.89
Protein/creatinine
ratio (mg/mgCr)
10.61 – 1.69
Serum
immunoﬁxation
Anti-kappa Anti-kappa Absent
Serum κ/λ ratio 5,113.1 591.55 7.20
Urine M protein
(mg/day)
2,911.6 649.1 98.2
n Treatment (thalidomide/cyclophosphamide/dexamethasone): from Octo-
ber 2012 to January 2013; autologous peripheral blood stem cell transplan-
tation: March 2013.
† One year after transplantation, she was taking 2,040mg of phosphate,
0.75 μg of calcitriol, 3,600 mg of potassium chloride, 100 mg of spironolac-
tone, and 3,000mg of sodium bicarbonate daily.
S.G., speciﬁc gravity.
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6 months. She did not appear to have edema or to gain weight.
She had no speciﬁc underlying disease or related family
history. However, she had been taking a course of Chinese
medicine for the past 6 months.
At presentation, her vital signs were stable (blood pressure:
128/80 mmHg, heart rate: 62 beats/minute, respiration rate:
18 breaths/minute, body temperature: 36.41C), and her general
physical examination was unremarkable.
Results from the blood testing, which included complete
blood count, coagulation test, total bilirubin, aspartate transami-
nase, alanine transaminase, cholesterol, glucose, erythrocyte
sedimentation rate, C-reactive protein, and thyroid function
test were in the normal range. The patient’s protein level was
6.6 g/dL and her albumin level was 4.9 g/dL, so her globulin was
low (1.6 g/dL). Her creatinine was 1.02 mg/dL, with a mildly
decreased estimated glomerular ﬁltration rate of 58 mL/minute/
1.73 m2. Hypouricemia (0.9 mg/dL) and hypophosphatemia
(2.3 mg/dL) were observed. Serum sodium/potassium/chloride
(139/3.5/109 mmol/L) and calcium (8.8 mg/dL) were in normal
ranges. Arterial blood gas analysis showed normal anion gap
metabolic acidosis (pH 7.324, pCO2 31.2 mmHg, pO2 108.9 mmHg,
HCO3 15.9 mmol/L).
Urine dipstick testing showed the following characteristics:
speciﬁc gravity (1.036), pH (6.5), blood (þ), albumin (þþ),
and glucose (þþ). A urine electrolyte test showed 51 mmol/L
of sodium and 23.5 mmol/L of potassium. Fraction excretion of
phosphorus was 44.17%, despite hypophosphatemia. Fraction
excretion of uric acid was also increased to 104.16% despite
hypouricemia. A spot urine test showed a urine protein/
creatinine ratio of 10.61 mg/mgCr and a urine albumin creati-
nine ratio of 401.69 mg/mgCr. Based on the above information,
we concluded that the patient had generalized proximal
tubular dysfunction and overﬂow proteinuria.
An anti-kappa abnormal band was observed in serum and
urine immunoﬁxation. The patient had an elevated serum
kappa/lambda ratio of 5,113.1. Through urine protein electro-
phoresis, the M peak was observed behind the beta globulin
region (2,911.6 mg/day).
Bone marrow examination showed normocellular marrow
with 24% CD138þ plasma cell staining with kappa restriction.
The patient was diagnosed with multiple myeloma (kappa
type) and FS.
A renal biopsy was performed for accurate diagnosis of
FS and to exclude renal amyloidosis or monoclonalFigure 1. Histopathologic features. (A) Minimal mononuclear cell inﬁltrati
and eosin (light microscope, 400). (B) Cytoplasm of proximal tubular epi
inclusions (arrow) (electron microscope, 17,000). (C) Numerous rod-sha
cytoplasm (arrow) (electron microscope,  55,000).immunoglobulin (Ig) deposition disease. The biopsy revealed
26 glomeruli, three of which showed global sclerosis. The other
glomeruli were unremarkable with no evidence of proteinous
deposits. Mesangial matrix was not increased. Capillary loops
were thin and delicate. Tubules revealed focal acute damage
without interstitial ﬁbrosis (Fig. 1A). Immunoﬂuorescence stain-
ing for IgA, IgG, IgM, C3, kappa, and lambda was negative.
Under electron microscopy, the glomerular basement mem-
brane was slightly irregular in contour with mild effacement of
epithelial foot processes. Numerous rod- or rhomboid-shaped
crystalline inclusions were present in the cytoplasm of prox-
imal tubular epithelial cells (Fig. 1B). Most of the crystalline
inclusions were electron dense and ﬂoating in the cytoplasm
(Fig. 1C). However, they were not found in the glomerular cellson with focal atrophy is seen in tubule after staining with hematoxylin
thelial cell contains multiple intracellular rectangular shape crystalline
ped and rhomboid-shaped crystalline inclusions are lying free within
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deposits, or immune type electron densities.
Finally, she was diagnosed as having multiple myeloma
(kappa type) with FS. Kidney pathology conﬁrmed the presence
of rod-shaped crystalline inclusions in proximal tubular cells.
The patient received four cycles of dexamethasone, cyclopho-
sphamide, and thalidomide. Autologous stem cell transplantation
with melphalan conditioning was performed 5 months after
diagnosis. The patient showed very good partial hematologic
response 3 months after stem cell transplantation. Her free
serum kappa/lambda ratio decreased to 5.5. Her 24-hour-urine
M-protein decreased to 80 mg/day. Plasma cells were observed
ino5% of aspirated bone marrow, although CD138þ cells were
counted in up to 5% of bone marrow with kappa restriction.
Currently, the patient has survived for 1 year after autologous
stem cell transplantation and she has received thalidomide
maintenance; however, her proximal tubular dysfunction has
not improved (Table 1).
Hypouricemia (1.3 mg/dL) and glycosuria were still
observed in her last laboratory tests. Phosphate level was
normal (3.0 mg/dL) under intake of 2,040 mg of phosphate
and 0.75 μg of calcitriol daily. To maintain a potassium level of
4 mmol/L and prevent metabolic acidosis, the patient was
taking 3,600 mg of potassium chloride, 100 mg of spironolac-
tone, and 3,000 mg of sodium bicarbonate daily. Urine albu-
min to creatinine ratio showed a similar level with baseline
(440 μg/mgCr) and urinary protein to creatinine ratio was
much decreased to 1.69 mg/mgCr, which reﬂected reduced
overﬂow proteinuria and persistent tubular proteinuria.Discussion
This patient presented with proteinuria and upon evalua-
tion was found to have normal anion gap metabolic acidosis,
normoglycemic glycosuria, hypophosphatemia, and hypouri-
cemia. Therefore, we suspected that she had FS. The M peak
behind the beta globulin region was detected by urine protein
electrophoresis. Bone marrow examination showed normocel-
lular marrow with 24% CD138þ plasma cells in kappa restric-
tion. Crystalline inclusions were observed in proximal tubular
cells on kidney biopsy. Therefore, she was diagnosed with
multiple myeloma and light chain proximal tubulopathy.
In multiple myeloma, renal insufﬁciency is a common
complication [5]. Up to 50% of patients with multiple myeloma
initially present with kidney injury. Acute renal failure in
myeloma is often caused by excessive production and ﬁltration
of free light chains.
Overproduced light chains can exert direct toxic effects
onto kidney cells and generate myeloma casts by binding to
Tamm-Horsfall proteins [4]. Cast nephropathy is the most
common pattern of renal parenchymal disease associated with
multiple myeloma [5]. Amyloidosis and monoclonal immuno-
globulin deposition disease are the other types of deposition
diseases that occur less frequently. Hypercalcemia, drug toxi-
city, and volume depletion also contribute to acute kidney
injury in multiple myeloma cases [4].
FS is a relatively uncommon renal manifestation of multiple
myeloma [5]. Excessively ﬁltrated monoclonal light chains,
usually composed of kappa light chains restricted to the Vκ I
subgroup, generate crystals within the cytoplasm of proximal
tubular epithelial cells [2]. These monoclonal kappa light chains
have variable domains that are resistant to degradation byproteases in lysosomes [6]. Mutations of variable domains of
kappa light chain, which is changing serine 30 to alanine,
isoleucine, or leucine residue, increase the hydrophobicity of
the CDR-L1 loop [7]. Fragments of the variable domain that
accumulate in the cytoplasm are responsible for intracellular
crystal formation and tubular dysfunction [8]. The crystalline
inclusions generated from light chains can induce cytot-
oxicity in the proximal tubular epithelial cells [2]. They are
associated with proximal tubular dysfunction including hypo-
phosphatemia, hypouricemia, aminoaciduria, glycosuria, and
metabolic acidosis [4]. Also, disruption of phagocytes that
contain crystals may induce tissue injury, subsequently leading
to tubular atrophy and interstitial ﬁbrosis [4].
It is unclear whether achieving a hematologic response by
treating multiple myeloma can resolve renal proximal tubular
dysfunction. Gailani et al [9] reported a hematologic response in
a myeloma case by irradiation, followed by melphalan, predni-
sone, and vincristine. After myeloma treatment, the patient’s
hypophosphatemia, hypouricemia, and glycosuria were normal-
ized. Uchida et al [10] found that after treatment for multiple
myeloma, urinary Bence-Jones protein disappeared and glyco-
suria, aminoaciduria, phosphaturia, and metabolic acidosis all
improved [10]. It was reported by von Scheele [11] that glyco-
suria improved in a patient with FS with myeloma after 6 weeks
of melphalan therapy; however, despite achieving a partial
hematologic response after myeloma therapy, renal tubular
acidosis, glycosuria, and hypophosphatemia persisted in the
patient.
Conservative management of FS is a correction for hypo-
phosphatemia [12]. It is important to prescribe both phosphate
and vitamin D to correct hypophosphatemia and to prevent
metabolic bone disease, because impairment of vitamin D
activation mechanisms also contributes to hypophosphatemia
in FS [13]. For normalization of metabolic acidosis, 10–15 mEq/
kg/day of sodium bicarbonate is required [12]. Because alkali
therapy may induce bicarbonaturia and urinary potassium
loss, patients should take a potassium supplement [14].
In conclusion, we report a case of FS without renal failure,
where the patient was ultimately diagnosed with multiple
myeloma, demonstrating crystalline inclusion in proximal
tubular cells on kidney biopsy. Adult patients with FS should
be evaluated for the presence of Bence-Jones proteinuria and
plasma cell dyscrasia should be excluded as an underlying
factor.Conﬂicts of interest
The authors declare no conﬂict of interest.
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